The liver and spleen are vital organs involved in drug clearance and maintenance of the hemostasis. Doxorubicin is an important chemotherapeutic agent used in the treatment of hematological cancers and solid tumors. We aimed to identify the protective impact of Coenzyme Q10 (CoQ10) against doxorubicin-induced normal tissue damage using the liver and spleen as a model. To do so, a total of 27 rats were used in this study and they were divided into three groups of 9 each. Group 1 received CoQ10 over 17 days with a single injection dose of normal saline at day 13. Group 2 received normal saline over 17 days with a single injection dose of doxorubicin at day 13. Group 3 received CoQ10 over 17 days with a single injection dose of doxorubicin at day 13. Spleen and liver were harvested and processed for slide preparation to be examined under a light microscope. The results confirmed that doxorubicin induced liver and spleen damage. The liver damage was evidenced by hepatic coagulative necrosis of hepatocytes, dilatation of sinusoids and congestion of portal vein, while spleen damage was evidenced by loss of white pulp with atrophy, hyaline degeneration of splenic artery, and necrosis of red pulp. CoQ10 reduced these damaging effects in both the spleen and liver to a large extent restoring the normal tissue architecture of liver and spleen. The present study concluded that CoQ10 can counteract the harmful effects of Doxorubicin and preserve the liver and spleen.